STOCK TITAN

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Bioventus Inc. (Nasdaq: BVS) will release its financial results for the first quarter of fiscal year 2024 on May 7, 2024. The management will conduct a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update. Participants can join the call by dialing 1-833-636-0497 or accessing the live webcast on the company's website. The webcast will be available for replay until May 6, 2025.

Positive
  • None.
Negative
  • None.

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 6, 2025.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com


FAQ

When will Bioventus report its financial results for the first quarter of fiscal year 2024?

Bioventus will report its financial results on May 7, 2024.

What time will the conference call to discuss the financial results take place?

The conference call will be at 8:30 a.m. Eastern Time on May 7, 2024.

How can one participate in the conference call?

To join the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

Where can the live webcast of the call be accessed?

The live webcast and accompanying materials will be provided on the 'Investor Relations' section of Bioventus' website at https://ir.bioventus.com/.

Until when will the webcast be available for replay?

The webcast will be archived at the same site and available for replay until May 6, 2025.

Bioventus Inc.

NASDAQ:BVS

BVS Rankings

BVS Latest News

BVS Stock Data

407.22M
23.20M
11.14%
66.3%
0.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
DURHAM

About BVS

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat